BRIEF-Health Canada Permits COVID-19 Patients With Respiratory Failure To Be Given Nuvox Pharma’s Oxygen Therapeutic In Segment Iia Clinical Trial

BRIEF-Health Canada Permits COVID-19 Patients With Respiratory Failure To Be Given Nuvox Pharma’s Oxygen Therapeutic In Segment Iia Clinical Trial

June 29 (Reuters) – Nuvox Pharma:

HEALTH CANADA ALLOWS COVID-19 PATIENTS WITH RESPIRATORY FAILURE TO BE GIVEN NUVOX PHARMA’S OXYGEN THERAPEUTIC IN PHASE IIA CLINICAL TRIAL

NUVOX PHARMA – RECEIVED “NO OBJECTION LETTER” FROM HEALTH CANADA TO PROCEED WITH PHASE IIA CLINICAL TRIAL OF NANO2 IN COVID-19 SUBJECTS WITH AHRF Source textual issue for Eikon: ]

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *